|
September 2002 (v02-n09) |
|
- Main Story - pgs. 1-9 Discovery Labs
- Special Section - pgs. 10-18 Psychotropic Medications
- Macro Market Commentary - pgs. 19-20
- NIBM Model Portfolio Updates - pg. 21
- Note to Subscribers - pg. 22
- NIBM Model Portfolio - pg. 23
|
 |
|
| This month's Main Story is a brief exploration
of Discovery Labs (NASDAQ:DSCO). This company makes a synthetic version
of the surfactant that allows the alveoli in your lungs to work. Initially targeted at
premature infants, this drug may well have the ability to treat adult diseases like ARDS
and COPD. Early data is promising and the company says they'll be able to go to an NDA in
2003. |
 |
|
| In a slight
departure, we also have a Special Section in this month's NIBM Newsletter. It is the follow-up to
last month's article on drugs for mental diseases. In this month's version, we examine a
sliver of the scientific basis of these psychotropic medications. We compare different
classes of medications together. We briefly map current medications and discuss the future
of these medications. |
|
|
| The following is an outline of this issue of
the NIBM Newsletter. |
Subscriber direct access |
|
| |
|
|
- Main Story - Discovery Laboratories
- Introduction
- Table: Basic Facts
- Disclosures
- Cash position and recent financings
- Table:
Funding sources
- Table:
Outstanding Warrants
- Investment case
-
- Product Pipeline
- Table: Discovery Labs surfactant product platform
-
- Surfaxin
- About surfactants
- Trials
- Table: Description of Surfaxin late stage trials
Manufacturing
- Partnerships
- Table: Partnerships
-
- Competition
- Table: Surfaxin Competitors
- Table Drug Product Comparisons
What Can Go Wrong
- Special Section - Psychotropic Medications
- Introduction
-
- How do psychotropic medications work
- Receptor subtypes
- Table: One family of dopamine receptors
- Table: Depression and neurotransmitter deficiency
- Table: Selected serotonin receptors
-
- Neuroanatomical region
- Table: Dopamine pathways and neuroanatomical regions
Combined effects of neurotransmission systems
- Depression
- Basic description
- Severe depression
- Sidebar: Basic Facts about Depression
- Market size
- Table: Leading antidepressants
- Current antidepressants
- MAO inhibitors (MAOIs)
- Tricyclic antidepressants (TCAs)
- Selective serotonin reuptake inhibitors (SSRIs)
- Selective norepinephrine reuptake inhibitors (SNRIs)
-
- Antidepressants in development
- Table: Some antidepressants in late clinical development
- Sidebar: Something new under the sun?
Macro Market Commentary
- NIBM Model Portfolio and Updates
- Dendreon
- Genta
- Indevus
- Targeted Genetics
- Esperion and Alteon
Note to Subscribers |
|
|
| |
|
|
 |
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
